Correction to: British Journal of Cancer (2020) 123, 1047–1059; https://doi.org/10.1038/s41416-020-0987-3, published online 22 July 2020
Since the publication of this paper, the authors have noticed that acknowledgement of the support given by COST (European Cooperation in Science and Technology) to the study was omitted from the Funding section. The complete Funding information is provided below. The authors would like to apologise for this oversight. The original article has been corrected.
Funding information
C.B. LKAS readership—University of Glasgow: J.J.G.M./R.I.R.M. Carlos III Institute of Health, Spain (PI16/00598); “Centro Internacional sobre el Envejecimiento”, Spain (OLD-HEPAMARKER, 0348-CIE-6-E); C.M.P.R. is supported by FEDER funds through the COMPETE programme and by national funds through Fundação para a Ciência e a Tecnologia (grants PTDC/MED-FAR/29097/2017 and SAICTPAC/0019/2015—LISBOA-01-0145-FEDER-016405). A.L. was part-funded by The Christie Charity. MGF-B is supported by grants SAF2014-54191-R and SAF2017-88933-R from FEDER/Ministerio de Ciencia, Innovación y Universidades-Agencia Estatal de Investigación; HEPACARE Project from Fundación La Caixa. J.M.B. was funded by Spanish Carlos III Health Institute (ISCIII) (FIS PI15/01132, PI18/01075 and Miguel Servet Program CON14/00129), cofinanced by “Fondo Europeo de Desarrollo Regional” (FEDER); AMMF (J.M. Banales and P.M. Rodrigues 2019/202); PSC Partners US; PSC Supports UK (06119JB); Horizon 2020 (H2020 ESCALON project: H2020-SC1-BHC-2018-2020); IKERBASQUE, Basque foundation for Science; CIBERehd (ISCIII); “Diputación Foral Gipuzkoa” (DFG15/010, DFG16/004), BIOEF (Basque Foundation for Innovation and Health Research); EiTB Maratoia (BIO15/CA/016/BD); Department of Health of the Basque Country (2017111010) and Euskadi RIS3 (2016222001, 2017222014, 2018222029 and 2019222054); La Caixa Scientific Foundation (HR17-00601); “Fundación Científica de la Asociación Española Contra el Cáncer” (AECC Scientific Foundation, to J.M. Banales and J.J.G. Marin). P.M.R. was funded by Spanish Carlos III Health Institute (ISCIII; Sara Borrell CD19/00254) cofinanced by “Fondo Europeo de Desarrollo Regional”. M.M. received PSA-2017-UNIVPM. P.A. is supported by a NIHR-Biomedical Research Centre funding (BRC646b/III/SP/101350). O.S. is funded by AIRC (IG2018, ID 21627, PI Segatto Oreste). A.V. is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - SFB/TRR 209 - 314905040, and Vo959/9-1. This work was performed under the frame of Working Group 6 of the COST Action CA18122 European Cholangiocarcinoma Network supported by COST (European Cooperation in Science and Technology) www.cost.eu.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Marin, J.J.G., Prete, M.G., Lamarca, A. et al. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer. Br J Cancer 125, 904 (2021). https://doi.org/10.1038/s41416-020-01243-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-020-01243-3